Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 611-631-1 | CAS number: 58190-57-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key study: Based on the read-across from experimental results on the analogue substance Wasox-VMAC2 (OECD Guideline 407, GLP study), the NOEL of EAC3 for 28 days oral exposure in rats was estimated to be 15.99 mg/kg bw/day.
Key study: Based on the read-across from experimental results on the analogue substance Wasox-MMAC2 (OECD Guideline 407, GLP study), the NOEL of EAC3 for 28 days oral exposure in rats was estimated to be 16.54 mg/kg bw/day.
Key study: Based on the read-across from experimental results on the analogue substance MIBKO (OECD Guideline 408, GLP study), the NOAEL of EAC3 for 90 days oral exposure in rats was estimated to be 11.87 mg/kg bw/day.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- EAC3 undergoes rapid hydrolysis in aqueous to acetone oxime and the corresponding ethylsilanetriol. Silanetriols undergo continuous condensation reactions to produce higher molecular weight siloxanes which are considered biologically unavailable. Therefore, the observed toxicity is likely due to the acetone oxime and their values are comparable. Moreover, the analogue methyl isobutyl ketoxime, which shares the same functional groups with acetone oxime, also has comparable values for the relevant molecular properties and they are toxicologically equivalent.
- Reason / purpose for cross-reference:
- reference to other study
- Principles of method if other than guideline:
- Read-across approach from experimental results (test method according to OECD Guideline 408, GLP study) on the analogue substance MIBKO
- GLP compliance:
- no
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- Based on the experimental results obtained in the analogue substance MIBKO, where the NOAEL for 90 days oral exposure in male and female rats was determined to be 15 mg/kg bw/day based on the effects on red blood cells, resulting in associated changes in the spleen), the read-across approach was applied and the NOAEL (90 days, oral) for EAC3 in rats was estimated to be 11.87 mg/kg bw/day in rats.
- Dose descriptor:
- NOEL
- Effect level:
- 11.87 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: (Read-across approach from an analogue substance) (Basis for effect: effects on red blood cells, resulting in associated changes in the spleen)
- Critical effects observed:
- not specified
- Conclusions:
- Based on the read-across approach from experimental data on analogue substance MIBKO (OECD Guideline 408, GLP study), the NOAEL of EAC3 for 90 days oral exposure in rats was determined to be 11.87 mg/kg bw/day.
- Executive summary:
A 90 days oral repeated dose toxicity test was performed on the analogue substance MIBKO according to OECD Guideline 407 and GLP. The NOAEL was determined to be 15 mg/kg bw/day in rats based on the effects on red blood cells, resulting in associated changes in the spleen were observed at 50 mg/kg bw/day. Based on these results, the read-across was applied and the NOAEL of EAC3 for 90 days oral exposure in rats was estimated to be 11.87 mg/kg bw/day under the test conditions (effects at an estimated concentration of 39.57 mg/kg bw/day).
Reference
See "Data Matrix" and "Reporting Format" attached.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 11.87 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- One 90 day and two 28 day exposure duration studies performed on an analogue substance, GLP compliant and Klimisch score = 2.The overall quality of the database was determined as appropriate for assessment.
Additional information
Key study: Read-across approach from experimental results on the analogue substance Wasox-VMAC2:
A repeated dose 28 -day oral toxicity study in rodents for the analogue substance Wasox-VMAC2 was performed in accordance with OECD Guideline 407 and GLP. The test material was administered groups of 5 rats per sex and dose, once a day for 28 consecutive days. The dose used were 0 (control) 20, 63, and 200 mg/kg/day, including satellites groups of the control and the highest dose with a 14 days observation period to analyse reversibility or persistence of test substance induced lesions. The effects noted at a dose of 200 mg/kg and below were mainly adaptations to damage to peripheral erythrocytes without an impairment of the blood cell production in the bone marrow. The NOEL was determined to be 20 mg/kg bw/day. Based on these results the read-across approach was applied and the NOEL of EAC3 for 28 days oral exposure in rats was estimated to be 15.99 mg/kg bw/day.
Key study: Read-across approach from experimental results on the analogue substance Wasox-MMAC2:
A repeated dose 28 -day oral toxicity study in rats was performed on the analogue substance Wasox-MMAC2 according to OECD Guideline 407 and GLP. The test material was administered by by gavage to 5 rats per sex and per group once a day for 28 consecutive days at a concentration of 0 (control) 20, 63, and 200 mg/kg/day. Reversibility or persistence was analysed by 2 groups of 5 males and 5 females each (high dose satellite group and control satellite group) for further 14 days without test substance administration. The NOEL was determined to be 20 mg/kg bw/day for both sexes since damages to mature erythrocytes in the peripheral blood, with a parallel marked increase production of your erythrocytes by the presence of hematopoiesis in the spleen was observed in higher doses. Based on these results, the read-across approach was applied and the NOEL of EAC3 for 28 days oral exposure in rats was estimated to be 16.54 mg/kg bw/day.
Key study: Read-across approach from experimental results on the analogue substance MIBKO:
A repeated dose 90 -day oral toxicity study in rats was performed on the analogue substance MIBKO according to OECD Guideline 408 and GLP. 4 groups each comprising 10 rats per sex were exposed to 0 (control) 5, 15 or 50 mg/kg/day. A further five male and five female were assigned to each of the groups which were treated for 13 weeks, followed by a 4 week period without treatment for recovery assessment. The principal action of MIBKO was to affect the red blood cell rate of turnover occurring mainly among animals receiving 50 mg/kg/day, resulting in associated changes in the spleen. A dosage level of 15 mg/kg/day, was considered to be the NOAEL for MIBKO in both sexes, as the changes observed at 5 and 15 mg/kg/day were considered to be minor in nature and had shown full recovery after 4 weeks without treatment. Based on these results, the read-across approach was applied and the NOAEL of EAC3 for 90 days oral exposure in rats was estimated to be 11.87 mg/kg bw/day.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
The study with the longest duration (90-days) was chosen (key study).
Justification for classification or non-classification
Based on the available data on a 90-day study, oral administration of the test material to rats affected the red blood cell turnover resulting in associated changes in the spleen at an estimated dose level of 39.57 mg/kg bw/day. Taking into account this information, the substance would be classified as STOT RE Category 2 (Specific target organ toxicity — repeated exposure) according to CLP Regulation (EC) nº 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.